HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio†or the "Company†), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2025, and provided recent corporate and pipeline updates. "Both tibulizumab studies advanced during the quarter,†said Kiran Nistala, MBBS, PhD, Chief Medical Officer and Head of Development at Zura Bio. "We ...